Second-line option for metastatic RCC

被引：0
|
作者：
Vanessa Marchesi
机构：
来源：
Nature Reviews Clinical Oncology | 2013年 / 10卷 / 6期
关键词：
D O I：
10.1038/nrclinonc.2013.74
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：305 / 305
相关论文
共 50 条
  • [21] IROX as second-line therapy for metastatic colorectal cancer
    Alberto Sobrero
    Nature Reviews Clinical Oncology, 2009, 6 : 248 - 250
  • [22] Options for Second-Line Treatment in Metastatic Colorectal Cancer
    Lee, James J.
    Sun, Weijing
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (01) : 46 - 54
  • [23] Cost Utility in Second-Line Metastatic Breast Cancer
    Gilles Berdeaux
    Patrick Hurteloup
    PharmacoEconomics, 1997, 11 : 492 - 495
  • [24] Capecitabine second-line monotherapy for metastatic breast cancer
    Vasev, N.
    Maneva, L.
    Smickoska, S.
    Arsovski, O.
    Stojkovski, I.
    Milanova, L.
    EJC SUPPLEMENTS, 2005, 3 (02): : 133 - 134
  • [25] Second-line systemic therapy for metastatic colorectal cancer
    Mocellin, Simone
    Baretta, Zora
    Roque i Figuls, Marta
    Sola, Ivan
    Martin-Richard, Marta
    Hallum, Sara
    Cosp, Xavier Bonfill
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (01):
  • [26] Second-line treatment of patients with metastatic colorectal cancer
    Rougier, P
    Lepere, C
    SEMINARS IN ONCOLOGY, 2005, 32 (06) : S48 - S54
  • [27] Irinotecan in second-line therapy of metastatic colorectal cancer
    Jäger, E
    Jäger, D
    Orth, J
    Knuth, A
    ONKOLOGIE, 2000, 23 : S15 - S17
  • [28] Second-line immunotherapy in patients with metastatic melanoma Comment
    Wong, Annie
    Gyorki, David E.
    LANCET ONCOLOGY, 2021, 22 (06): : 746 - 748
  • [29] IROX as second-line therapy for metastatic colorectal cancer
    Sobrero, Alberto
    NATURE REVIEWS CLINICAL ONCOLOGY, 2009, 6 (05) : 248 - 250
  • [30] Cost utility in second-line metastatic breast cancer
    Berdeaux, G
    Hurteloup, P
    PHARMACOECONOMICS, 1997, 11 (05) : 492 - 495
12345